摘要
H因子结合蛋白(factor H-binding protein, fHbp)是脑膜炎奈瑟菌(简称脑膜炎球菌)表面的一种关键毒力调节因子。fHbp通过与其配体H因子结合,使得脑膜炎球菌逃避人体免疫系统的识别和攻击,进而可在人体血液中生存,可引起脑膜炎和败血症等临床表现。由于B群脑膜炎球菌(Meningitidis serogroup B,MenB)荚膜多糖与人体神经组织具有相似性,因而荚膜多糖不适合作为疫苗的抗原成分。MenB疫苗大多采用蛋白疫苗的研发路线,研究人员通过反向疫苗学技术确定了fHbp及其他膜蛋白的免疫效果,其中fHbp是最有潜力的疫苗候选抗原成分,且该蛋白是目前已上市的MenB疫苗(Trumenba~?和Bexsero~?)的共有成分。现就fHbp作为MenB疫苗的抗原成分在疫苗中的研究进展作一概述。
Factor H binding protein(fHbp) is a key virulence regulator on the surface of Neisseria meningitidis(Nm),and its binding to its ligand, factor H,allows Neisseria meningitidis to evade killing by the human immune system and survive in human blood, thereby causing meningitis and sepsis, et al. Due to the similarity of serogroup B meningococcal capsular polysaccharides to human nervous tissue, they are not suitable as antigenic components of vaccines. Thus most of serogroup B meningococcol vaccines were focused on protein antigens. Researchers have discovered the fHbp protein and other membrane proteins by means of reverse vaccinology, in which fHbp is the most promising candidate antigen components for vaccines. fHbp is also a common component of the currently marketed Trumenba~? and Bexsero~? vaccines. An overview of the research and application of fHbp as an antigenic component of serogroup B meningococcal vaccines is presented.
作者
吴瑞(综述)
刘方蕾(审校)
WU Rui;LIU Fanglei(The First Research Department,Lanzhou Institute of Biological Products Co.,Ltd.,Center for Gansu Provincial Vaccine Engineering Research,Lanzhou 730046,Gansu Province,China)
出处
《微生物学免疫学进展》
CAS
2024年第2期100-105,共6页
Progress In Microbiology and Immunology
关键词
H因子结合蛋白
融合蛋白
表达量
免疫原性
五价联合疫苗
Factor H binding protein
Fusion protein
Expression level
Immunogenicity
Pentavalent combination vaccine
